PubMed · 14911684
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
G CASTELAIN, C CASTELAIN. 1951-12-25. [Tissue smears; diagnostic and cytologic method].. https://pubmed.ncbi.nlm.nih.gov/14911684/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
BACKGROUND: Although cytologic evaluation of urine specimens is a standard procedure in the diagnosis and follow-up of bladder carcinoma, its sensitivity and specificity are low. Cytopathologic diagnoses are driven primarily by spatial relations or morphology. Although color enhances the pathologist's perception of the specimen, spectral information plays a minimal role in diagnostic processes. Recently, methods have been developed to capture and analyze spectral information from clinical specimens. In the current study, the authors determined the classification value of spectral information by testing its ability to discriminate between malignant and benign urothelial cells in cytology specimens. METHODS: Multiple images of benign urothelial cells (n = 39) and urothelial carcinoma cells (n = 35) were collected at serial wavelengths using a liquid crystal tunable optical filter and composited into a mosaic using ENVI (Environment for Visualizing Images) software. Through minimum noise fractionation and principal component analysis, the spectral information in the mosaic was compressed into a 29-dimensional scatter plot. The data generated were analyzed using visual and spectral end member extraction on both the original data set and a second independent data set (test set). RESULTS: One area of spectral clustering in the scatter plot segmented with carcinoma cells exclusively (100% specific), but was not present in every cell (approximately 50%), which may indicate that these spectral profiles are present in a subpopulation of malignant cells or at specific points of their cell cycle. Using ENVI algorithms, the authors found that a particular classification spectrum (end member 9) and its closest relatives identified malignant cell clusters, with a sensitivity and specificity that reached 82% and 81%, respectively. To validate this mechanism in a test set, a second mosaic comprised of 15 benign and 15 malignant clusters was analyzed using end member 9, resulting in a combined sensitivity and specificity of 73%. CONCLUSIONS: The results of the current study demonstrate that spectral information, in the complete absence of morphologic or spatial information, allows discrimination of benign and malignant urothelial cells in routine urine cytology specimens. The authors believe that this novel technology, combined with spatial analysis, has the potential to serve as an ancillary test for improved detection of bladder carcinoma.
Explore the source record for details and available documents.
Slide-based cytometry (SBC) and related techniques offer unique tools to perform complex diagnostic procedures at very early disease stages. Multicolor or polychromatic analysis of cells by SBC is of special importance, not only as a cytomics technology platform, but for patients with low blood volume such as neonates. The exact knowledge of the location of each cell on the slide allows the specimen to be restained and subsequently reanalyzed. These separate measurements can be fused to one data file (merging), increasing the information obtained per cell. Relocalization and optical evaluation of the cells, a typical feature of SBC, can be of integral importance for cytometric analysis. Predictive medicine is aimed at the detection of changes in the patient's state prior to the manifestation of deterioration or improvement. Such instances are concerned with multiorgan failure in sepsis or noninfectious posttraumatic shock in intensive care patients, or the pretherapeutic identification of high risk patients in cancer cytostatic therapy. Early anti-infectious or anti-shock therapy, as well as curative chemotherapy in combination with stem cell transplantation, may provide better survival chances for the patient as well as concomitant cost containment. Predictive medicine-guided, individualized, early reduction or cessation of therapy may lower or abrogate potential therapeutic side effects (individualized medicine). With the 8th Leipziger Workshop and the 1st International Workshop on Slide-Based Cytometry, cytomics technologies moved to more practical applications in the clinics and the clinical laboratory. This development will be continued in 2004, at the upcoming Leipziger Workshop and the International Workshop on Slide-Based Cytometry.